Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 4Phase 3 3

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × AZD5305 × Clear all
NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

AstraZeneca

Phase 1 Active not recruiting
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT06713369 2026-03-04

AZD5305

AstraZeneca

Phase 1 Recruiting
8 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05938270 2026-02-24

ASCERTAIN

AstraZeneca

Phase 1 Recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT05573724 2024-06-18

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡